Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01787305 · ClinicalTrials.gov registry record

Pilot Study of Gut Commensals in Antiphospholipid Syndrome

A clinical trial of Antiphospholipid Syndrome (APS), sponsored by Yale University.

Active
Registry status
16
Enrollment target
1
Study location

NCT01787305 is a study of Antiphospholipid Syndrome (APS) that is active but no longer recruiting, run by Yale University. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01787305, a study of Antiphospholipid Syndrome (APS), is active but no longer recruiting, sponsored by Yale University.

ACTIVE NOT RECRUITING
Registry status
16 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to explore if certain commensals within the gut microbiota (the collection of all microbes that live inside the gut) correlate with autoantibodies in the autoimmune clotting disorder called antiphospholipid syndrome. The study hypothesis is that particular commensals induce the autoantibodies (immune molecules that bind to self structures) and thus correlate with the level of immune cells and antibodies that are self-reactive. Participants are patients with antiphospholipid syndrome and individuals who have tested positive on a prior blood test for anti-beta2-glycoprotein I antibodies or those that have tested negative for antiphospholipid antibodies in their blood, but had a clotting event or a health problem that puts them at risk to form blood clots.

Study Locations (1)

Connecticut

  • Yale University School of Medicine; Yale-New Haven Hospital - New Haven

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2013-02
Est. Completion 2026-12

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT01787305

The ClinicalTrials.gov registry entry for NCT01787305 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Antiphospholipid Syndrome (APS) appearing as the primary indexed condition, and to 0 interventions.

NCT01787305 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT01787305 about?

NCT01787305 is a clinical study titled "Pilot Study of Gut Commensals in Antiphospholipid Syndrome". The purpose of this study is to explore if certain commensals within the gut microbiota (the collection of all microbes that live inside the gut) correlate with autoantibodies in the autoimmune clotting disorder called antiphospholipid syndrome. The study hypothesis is that particular commensals ind...

What is the current status of trial NCT01787305?

This trial is currently active not recruiting. The enrollment target is 16 participants. The study started on 2013-02. Estimated completion is 2026-12.

What conditions does trial NCT01787305 study?

This clinical trial studies the following conditions: Antiphospholipid Syndrome (APS).

Who is sponsoring clinical trial NCT01787305?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01787305 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Antiphospholipid Syndrome (APS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.